# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2015 Earnings Results

**Report date:** 2015-05-07 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2015

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.3%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.88 | N/A | +48.45% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's product pipeline and market position. However, they did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They emphasized ongoing investment in research and development.

> No specific guidance was provided for future quarters.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a strong earnings surprise with an EPS of $2.88, significantly above expectations. Despite this positive news, the stock fell by 0.3% in reaction, indicating that investors may have been looking for more clarity on future revenue and guidance. The lack of revenue details and guidance may have contributed to the stock's slight decline.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2015_